C4-BIOC
Collagenase Type IV, Cls IV
Synonym(s):
Collagen A, Type IV Gelatinase
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.78
UNSPSC Code:
12352204
General description
Collagenase Type IV, Cls IV is a member of the mammalian extracellular neutral metalloproteinases family. It digests type IV collagen, which is a major structural constituent of the basement membrane.
This product is identical to Biochrom GmbH part numbers C4-22 and C4-28. Enzyme blending from collagenase, clostripain, with tryptic and proteolytic activities. Recommended for the isolation of Islets of Langerhans. Specific activity is 125 to 250 Mandl units per milligram of powdered substance.
Application
Collagenase Type IV, Cls IV may be used:
- as a component in Dulbecco′s modified Eagle′s medium (DMEM)/F12 to digest endometrial samples isolated from in vitro fertilization (IVF) patients
- for collagenase perfusion to isolate hepatocytes using collagenase-liver perfusion method in rats
- in the isolation of rat glomerular endothelial cells (GEndCs)
Regulatory Information
常规特殊物品
常规特殊物品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Hyun-Jeong Cho et al.
Biological & pharmaceutical bulletin, 28(8), 1418-1423 (2005-08-05)
Microsomal triglyceride (TG) transfer protein (MTP) is involved in the secretion of TG-rich very low-density lipoprotein (VLDL), a process which leads to the generation of hypertriglyceridemia and atherosclerosis. We investigated the possible role of Ca(2+) on MTP activity in hepatocytes.
P Huhtala et al.
The Journal of biological chemistry, 265(19), 11077-11082 (1990-07-05)
The structure of the gene for human 70-kDa type IV collagenase (gelatinase) was determined. Three overlapping genomic clones were isolated and shown to contain 0.4 kilobase (kb) of the 5'-flanking region, the 27-kb structural gene, and 4.5 kb of the
Zongliang Zhang et al.
Journal of translational medicine, 21(1), 23-23 (2023-01-13)
Chimeric antigen receptor (CAR) T cells and immune checkpoint blockades (ICBs) have made remarkable breakthroughs in cancer treatment, but the efficacy is still limited for solid tumors due to tumor antigen heterogeneity and the tumor immune microenvironment. The restrained treatment